These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7591476)

  • 21. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
    Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
    J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India.
    Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A
    Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leishmanin and tuberculin sensitivity in leishmaniasis in the Sudan, with special reference to kala-azar.
    Zijlstra EE; el-Hassan AM
    Trans R Soc Trop Med Hyg; 1993; 87(4):425-7. PubMed ID: 8249072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 26. Kala-azar (visceral Leishmaniasis) from Khotang.
    Joshi S; Bajracharya BL; Baral MR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):232-4. PubMed ID: 18603904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Visceral kala-azar associated with post-kala-azar dermal leishmaniasis.
    Singh NK; Agrawal SK; Jha TK
    J Assoc Physicians India; 1989 Feb; 37(2):191. PubMed ID: 2808294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visceral leishmaniasis (kala-azar) and pregnancy.
    Figueiró-Filho EA; Duarte G; El-Beitune P; Quintana SM; Maia TL
    Infect Dis Obstet Gynecol; 2004; 12(1):31-40. PubMed ID: 15460194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ketoconazole in the treatment of antimony- and pentamidine-resistant kala-azar.
    Wali JP; Aggarwal P; Gupta U; Saluja S; Singh S
    J Infect Dis; 1992 Jul; 166(1):215-6. PubMed ID: 1607703
    [No Abstract]   [Full Text] [Related]  

  • 30. Maternal and perinatal outcomes of visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern Sudan.
    Adam GK; Abdulla MA; Ahmed AA; Adam I
    Int J Gynaecol Obstet; 2009 Dec; 107(3):208-10. PubMed ID: 19766208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
    Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P
    J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
    Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
    J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of kala-azar treated with a new antimony].
    NAUSSAC ; PELLERAT ; GONNET L
    Lyon Med; 1947 May; 177(20):334-9. PubMed ID: 20268746
    [No Abstract]   [Full Text] [Related]  

  • 35. Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.
    Trindade MA; Silva LL; Braz LM; Amato VS; Naafs B; Sotto MN
    BMC Infect Dis; 2015 Nov; 15():543. PubMed ID: 26592919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-kala-azar dermal leishmaniasis and visceral leishmaniasis in a child--or is it para-kala-azar dermal leishmaniasis?
    Mendiratta V; Chander R
    Int J Dermatol; 2009 Sep; 48(9):1027-8. PubMed ID: 19703001
    [No Abstract]   [Full Text] [Related]  

  • 37. Visceral leishmaniasis (kala-azar) as a cause of fever of unknown origin.
    Geraci JE; Wilson WR; Thompson JH
    Mayo Clin Proc; 1980 Jul; 55(7):455-8. PubMed ID: 6247584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does antimony therapy cause bleeding in kala-azar patients and why?
    Chowdhury MA; Ahasan HA; Azhar MA; Rafiqueuddin AK; Islam MR; Misbahuddin M; Rashid MU
    Trop Doct; 1995 Oct; 25(4):188-9. PubMed ID: 7502336
    [No Abstract]   [Full Text] [Related]  

  • 39. [Visceral leishmaniasis (kala-azar): 1st case observed in Chile].
    Osorio G; Moyano C; Caravagno C; Miranda C; Ubilla M; Maturana G; Retamales I
    Rev Med Chil; 1984 Mar; 112(3):261-6. PubMed ID: 6473968
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of kala azar.
    Ozsoylu S
    Lancet; 1996 Jun; 347(9016):1701. PubMed ID: 8642997
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.